Search PubMed⌕ Search

Biomedical subjects

D Selva

Publications and source records attributed to D Selva.

At least 37 records · Page 2Linked to original sources
PubMed2001

Orbital venous-lymphatic malformations (lymphangiomas) mimicking cavernous hemangiomas.

PURPOSE: To illustrate that orbital venous-lymphatic malformations (lymphangiomas) may rarely simulate cavernous hemangiomas. METHODS: Retrospective case review. RESULTS: Five patients were identified from a series of 85 patients with venous-lymphatic malformations. The age range was 21 to 69 years, and all cases presented with a history of slowly progressive or long-standing proptosis. Computerized tomography revealed relatively homogeneous intraconal masses that were well defined anteriorly. Two of the cases had expansion of the orbit, and one had focal calcification. The three who had magnetic resonance imaging showed heterogeneous contrast enhancement. The preoperative diagnosis in every case was cavernous hemangioma, and intraoperatively the lesions resembled cavernous hemangiomas. However, posterior dissection was difficult in all patients because of dense adhesions and, in one case, led to a central retinal artery occlusion. The histology was characteristic of orbital venous-lymphatic malformations in all five cases. CONCLUSIONS: Deep orbital venous-lymphatic malformations presenting in adulthood may be rarely confused with cavernous hemangiomas. In doubtful cases, significant intralesional heterogeneity, best seen on magnetic resonance imaging, and focal calcification may help distinguish the two entities. This differentiation is important, because dissection of venous-lymphatic malformations is fraught with more complications than surgical excision of a cavernous hemangioma.

Adult↗
PubMed2000

Orbital granulomatous giant cell myositis: a case report and review.

To present a case of orbital granulomatous giant cell myositis and review the literature. We describe the case of a 51-year-old woman, with a past history of melanoma, who presented with an acutely painful orbital myositis. This evolved into a chronic relapsing process involving multiple muscles bilaterally; which demonstrated partial steroid responsiveness. Biopsy revealed a granulomatous giant cell myositis. Orbital granulomatous giant cell myositis is a rare histological entity which has an association with giant cell myocarditis and underlying malignancy.

Anti-Inflammatory Agents↗
PubMed1998

Optic disc swelling in Crohn's disease.

PURPOSE: To provide a review of the causes of optic disc swelling in patients suffering from inflammatory bowel disease. METHODS: Two illustrative cases of bilateral optic disc swelling are presented: one in a patient known to have Crohn's disease and the other in a patient whose investigations revealed the disease. The possible causes of optic disc swelling in inflammatory bowel disease, based on a literature review, are tabulated and discussed with reference to the presented cases. RESULTS/CONCLUSIONS: Optic disc swelling is a rare complication of inflammatory bowel disease. Previously reported cases have been attributed to peripapillary inflammation, optic disc ischaemia or intracranial hypertension. Postulated causes of optic nerve ischaemia include a local vasculitis or general hypercoagulability. The underlying aetiology of intracranial hypertension is often elusive. Older studies suggest a relationship between corticosteroid treatment and/or iron deficiency anaemia, while modern imaging emphasises the need to exclude dural venous sinus thrombosis.

Adult↗
PubMed1986

Highly selective antiinflammatory and analgesic activity of 3-(1-methylethyl)-2-(4-methoxyphenyl)-3H-naphth[1,2-d]imidazole, a new non-acidic molecule.

3-(1-Methylethyl)-2-(4-methoxyphenyl)-3H-naphth[1,2-d] imidazole (MDL-035) has antiinflammatory activity in various antiinflammatory models such as carrageenin and nystatin oedemas, cotton pellet granuloma and adjuvant arthritis. The antiinflammatory potency of MDL-035 is greater than that of acetylsalicylic acid and phenylbutazone, but lower than that of indomethacin. MDL-035 has practically no gastroulcerogenic activity in rats, does not affect water or salt excretion, has no hormonal or antihormonal effects and has no other unwanted pharmacological effects. Its acute toxicity is very low.

Animals↗
PubMed1984

MDL-646, a new synthetic E1-prostaglandin with local protective effects on the gastric mucosa.

The gastric protection, diarrheogenic and arterial hypotensive effects of MDL-646, a PGE1 derivative, have been studied in rats. The compound administered p.o. or i.v. was able to inhibit the macroscopic damage to gastric mucosa produced by noxious stimuli (ethanol and indomethacin). In the stomach perfusion test with the anesthetized rat, intravenously administered MDL-646 reduced histamine- or pentagastrin-stimulated gastric secretion. After intraduodenal administration (i.d.) doses at least 40-50 times greater were necessary for an antisecretory effect. In conscious rats with chronic gastric fistulas, intragastrically administered (i.g.) MDL-646 affected both acid concentration and volume of unstimulated gastric secretion. In experimental models for gastric lesions, MDL-646 was much more potent after oral (p.o.) (15-30 times) than after i.v. administration. (ED50 micrograms/kg: vs. alcohol lesions, 0.05 p.o. and 0.7 i.v.; vs. indomethacin ulcers, 7.0 p.o. and 195 i.v.). Our data would fit the hypothesis that it was a local effect on the gastric mucosa. The mechanism of this effect is not known. The supposed local activity coupled with the antisecretory effects and the good tolerability make it interesting to test MDL-646 as an anti-ulcer agent in man.

Alprostadil↗
PubMed1984

Inhibition of PG production by MDL 035, a new non-steroidal non-acidic anti-inflammatory compound, in rat gastric mucosa and inflammatory exudate.

The effects of 3-(1-methylethyl)-2-(4-methoxyphenyl)-3H-naphth [1,2-d]imidazole, MDL 035, a new non-steroidal non-acidic anti-inflammatory compound, on the production of prostaglandin (PG) in rat gastric mucosa in vivo and in vitro and in inflammatory exudate in vivo were studied. MDL 035 reduced PGE2 and 6-keto-PGF1 alpha levels more effectively in inflamed tissue than in gastric mucosa when assayed in in vivo experiments, whereas indomethacin and other non-steroidal anti-inflammatory drugs (NSAIDS) are equally effective in both systems. MDL 035 is almost as active as indomethacin when incubated with gastric tissue in vitro. The better gastric tolerance of MDL 035 than of other NSAIDS is discussed in relation to these differences in in vivo and in vitro effects.

6-Ketoprostaglandin F1 alpha↗
PubMed1984

3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents.

Novel 3-alkyl-2-aryl-3H- naphth [1,2-d]imidazoles were synthesized and evaluated as antiinflammatory agents in the carrageenin-induced paw edema, cotton pellet induced granuloma, and adjuvant-induced polyarthritis assays in rats. The analgesic, antipyretic, and gastroulcerogenic effects were also tested. Structure-activity relationships are discussed. One of the compounds, 3-(1-methylethyl)-2-(4-methoxyphenyl)-3H- naphth [1,2-d]imidazole (35), was selected for clinical trials as a nonacidic antiinflammatory and analgesic agent.

Animals↗
PubMed1984

Antiinflammatory properties of a series of 4-amino-5-arylpyrazoles.

A series of ethyl 4-amino-5-arylpyrazol-3-yl carboxylates were prepared from arylacetonitriles and ethyl diazoacetate. The compounds were evaluated for their analgesic and antiinflammatory properties, that were not, however, sufficiently interesting to justify the further development of the compounds. The synthesis of the compounds could be a useful extension of the original report by A. Bertho on the reaction between ethyl cyanoacetate and ethyl diazoacetate to yield diethyl 4-aminopyrazole-3,5-dicarboxylate.

Animals↗
PubMed1982

[Unexpected anti-inflammatory activity of rigid structures derived from antihypertensive 6-arylpyridazinones. III. Synthesis and activity of 7-fluoro- and 5-keto-5H-indeno(1,2-c)pyridozines].

5H-Indeno[1,2-c]pyridazine (Ia) and its 3-oxo- and 4,4a-dihydro-3-oxo derivatives, already known to have antiinflammatory activity, were subjected to 7-fluoro substitution or to oxidation of the 5-methylene to a carbonyl group. The pharmacological evaluation of the resulting compounds indicated that the antiinflammatory activity disappeared in the fluoro derivatives, while it was still present in the 5-keto derivatives (I e), (II c). Moreover, the analgesic-antipyretic component of (I e) proved to be strongly enhanced compared with that of (I a).

Animals↗
PubMed1980

Antiinflammatory activity and other pharmacological properties of 11 beta, 21-dihydroxy-2'-methyl-5' beta H-pregna-1,4 dieno[17,16-d] oxazole 3,20-dione-21-acetate (Deflazacort).

The pharmacology of 11 alpha, 21-dihydroxy-2'-methyl-5' beta H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione-21-acetate (deflazacort) was studied by oral and parenteral administration in acute, short- and long-term experiments in rats. Deflazacort has antiinflammatory activity in various laboratory models, such as carrageenin and nystatin oedema, cotton pellet granuloma, adjuvant arthritis and on liver glycogen storage. The antiinflammatory potency of deflazacort is greater than that of prednisolone, but lower than that of dexamethasone. Absorption from the gut and duration of action appear to be highly satisfactory, as deduced from pharmacological and biochemical measurements. Glucose tolerance curves seem less affected by deflazacort than by prednisolone, while cardiovascular and central nervous system findings do not show unexpected responses.

Animals↗
PubMed1979

Synthesis and anti-inflammatory properties of some pyrrolo(1H,3H)[3,4-d]pyrimidin-2-ones and pyrrolo(1H,6H)[3,4-d]pyrimidin-2-ones.

The unequivocal synthesis of some terms belonging to the two isomeric classes of the pyrrolo(1H,3H)[3,4-d]pyrimidin-2-ones and of the pyrrolo(1H,6H)[3,4-d]pyrimidin-2-ones is reported. Some of these compounds are active in inhibiting the development of the carrageenin edema, of the granuloma cotton pellet and of the adjuvant arthritis in the rat when administered orally.

Animals↗